CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation

Metastatic castration-resistant prostate cancer (CRPC) is a fatal disease, primarily resulting from the transcriptional addiction driven by Androgen Receptor (AR). First-line CRPC treatments typically target AR-signaling, but are rapidly bypassed, resulting in only a modest survival benefit with the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Discov
Egile Nagusiak: ur Rasool, Reyaz, Natesan, Ramakrishnan, Deng, Qu, Aras, Shweta, Lal, Priti, Sander Effron, Samuel, Mitchell-Velasquez, Erick, Posimo, Jessica M., Carskadon, Shannon, Baca, Sylvan C., Pomerantz, Mark M., Siddiqui, Javed, Schwartz, Lauren E., Lee, Daniel J., Palanisamy, Nallasivam, Narla, Goutham, Den, Robert B., Freedman, Matthew L., Brady, Donita C., Asangani, Irfan A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7202356/
https://ncbi.nlm.nih.gov/pubmed/31466944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0189
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak